The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. (Q36615770)
Jump to navigation
Jump to search
scientific article published on 7 November 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. |
scientific article published on 7 November 2012 |
Statements
1 reference
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. (English)
1 reference
A Schneeweiss
1 reference
W Eiermann
1 reference
M Rezai
1 reference
S Kümmel
1 reference
T Kühn
1 reference
M Warm
1 reference
K Friedrichs
1 reference
S Markmann
1 reference
H Eggemann
1 reference
J Hilfrich
1 reference
C Jackisch
1 reference
I Witzel
1 reference
H Eidtmann
1 reference
A Bachinger
1 reference
S Hell
1 reference
J Blohmer
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference